Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Yeni P, Strohmaier KM, Rodgers AJ, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.

Antivir Ther. 2015;20(3):307-15. doi: 10.3851/IMP2912. Epub 2014 Oct 27.

2.

Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B.

Antimicrob Agents Chemother. 2014 Jul;58(7):3585-98. doi: 10.1128/AAC.00076-14. Epub 2014 Apr 14.

3.

Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.

Bao Y, Tian D, Zheng YY, Xi HL, Liu D, Yu M, Xu XY.

PLoS One. 2014 Feb 19;9(2):e89291. doi: 10.1371/journal.pone.0089291. eCollection 2014.

4.

Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.

von Wyl V, Klimkait T, Yerly S, Nicca D, Furrer H, Cavassini M, Calmy A, Bernasconi E, Böni J, Aubert V, Günthard HF, Bucher HC, Glass TR; Swiss HIV Cohort Study.

PLoS One. 2013 Oct 16;8(10):e77691. doi: 10.1371/journal.pone.0077691. eCollection 2013.

5.

Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.

Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K; UK Register of HIV.

PLoS One. 2013 Sep 24;8(9):e75608. doi: 10.1371/journal.pone.0075608. eCollection 2013.

6.

The emergence of drug resistant HIV variants and novel anti-retroviral therapy.

Paydary K, Khaghani P, Emamzadeh-Fard S, Alinaghi SA, Baesi K.

Asian Pac J Trop Biomed. 2013 Jul;3(7):515-22. doi: 10.1016/S2221-1691(13)60106-9. Review.

7.

Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.

Chen L, Ao Z, Jayappa KD, Kobinger G, Liu S, Wu G, Wainberg MA, Yao X.

Antimicrob Agents Chemother. 2013 Aug;57(8):3547-54. doi: 10.1128/AAC.00100-13. Epub 2013 May 13.

8.

Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011.

Bontell I, Häggblom A, Bratt G, Albert J, Sönnerborg A.

PLoS One. 2013;8(3):e59337. doi: 10.1371/journal.pone.0059337. Epub 2013 Mar 22.

9.

What do molecules do when we are not looking? State sequence analysis for stochastic chemical systems.

Levin P, Lefebvre J, Perkins TJ.

J R Soc Interface. 2012 Dec 7;9(77):3411-25. doi: 10.1098/rsif.2012.0633. Epub 2012 Sep 12.

10.

Controlling the HIV/AIDS epidemic: current status and global challenges.

Demberg T, Robert-Guroff M.

Front Immunol. 2012 Aug 14;3:250. doi: 10.3389/fimmu.2012.00250. eCollection 2012.

11.

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN.

PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.

12.

Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H.

Antimicrob Agents Chemother. 2012 Nov;56(11):5998-6000. doi: 10.1128/AAC.01217-12. Epub 2012 Aug 13.

13.

Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study.

Pefura Yone EW, Kengne AP, Ashuntantang G, Betyoumin AF, Ngogang J.

BMJ Open. 2012 Aug 8;2(4). pii: e001317. doi: 10.1136/bmjopen-2012-001317. Print 2012.

14.

Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA.

Graham SM, Jalalian-Lechak Z, Shafi J, Chohan V, Deya RW, Jaoko W, Mandaliya KN, Peshu NM, Overbaugh J, McClelland RS.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):511-8. doi: 10.1097/QAI.0b013e31825bd703.

15.

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina JM, de Truchis P.

PLoS One. 2012;7(5):e36673. doi: 10.1371/journal.pone.0036673. Epub 2012 May 10.

Supplemental Content

Support Center